+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 17 Actively Recruiting clinical trials

S

Actively Recruiting

Researchers are evaluating the safety and effects of a new drug called NNC0487-0111 in people with Heart Failure with preserved Ejection Fraction HFpEF or Heart Failure with mildly reduced Ejection Fraction HFmrEF who also have excess body weight. This study compares NNC0487-0111 against a placebo to determine if it is safe and effective for treating these heart conditions in people with obesity. The study is a randomized, controlled trial conducted by Novo Nordisk AS. Participants will receive either NNC0487-0111 or a placebo by subcutaneous injection once a week. The study drug dose may increase over time for those receiving NNC0487-0111. Treatment assignment is random, and the study includes a parallel design with two groups one receiving the experimental drug and one receiving placebo. The treatment period and monitoring last up to 165 weeks. During the study, participants will be monitored for heart failure events, cardiovascular death, hospital visits related to heart failure, and other major cardiovascular outcomes. They will complete questionnaires about their heart failure symptoms and quality of life. Kidney function will also be assessed in some participants. Safety and effectiveness will be evaluated throughout the study period, which can last over three years, with regular visits for injections and assessments.

Age: 18Years +All GendersPhase 3
838 locations
S

Actively Recruiting

Researchers are evaluating the safety of maribavir in adults who have severe chronic kidney disease CKD or end-stage renal disease ESRD, including those on dialysis, and who have a refractory cytomegalovirus CMV infection after transplantation. This observational study collects already existing data from participants medical records without changing their standard medical care or treatment. The study includes adults aged 18 years or older who have undergone solid organ or stem cell transplantation and have been treated with maribavir for refractory CMV infection. Data will be collected from the start of maribavir treatment through up to seven days after the last dose or until death or end of available data, whichever comes first. Participants include those with severe CKD or ESRD, including those on peritoneal or hemodialysis. Participants medical records will be reviewed to monitor any adverse events from maribavir treatment during the study period, which can last up to four years. The main measurement is the number of participants experiencing adverse events, including those of special interest. This review will not affect participants usual care, and no new treatments or interventions will be given as part of this study.

Age: 18Years +All Genders
25 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of pumitamig combined with chemotherapy compared to bevacizumab combined with chemotherapy in adults with previously untreated, unresectable, or metastatic colorectal cancer. This phase 23 study aims to provide important information on treatment options for this type of advanced colorectal cancer. Participants will receive different combinations of study drugs, including pumitamig or bevacizumab, along with chemotherapy regimens such as FOLFOX, FOLFIRI, or CAPOX. The dosages are specified and given on designated days. The study uses a randomized, double-blind design to compare these treatments across multiple groups. During the study, participants will be closely monitored for tumor response, progression-free survival, and overall survival for up to five years. Evaluations include tumor measurements using RECIST criteria, safety assessments, and other clinical tests. This long-term follow-up helps researchers understand how well the treatments work and their effects over time.

Age: 18Years +All GendersPhase 2Phase 3
286 locations
A

Actively Recruiting

Researchers are evaluating whether apixaban, an oral anticoagulant tablet, can reduce blood clots in people with lung cancer who are receiving chemotherapy or similar systemic anticancer treatments. Venous thromboembolism VTE is a common and serious complication in lung cancer patients undergoing such therapies, leading to poorer quality of life, higher healthcare costs, and increased morbidity and mortality. Current standard care does not routinely use blood thinners for outpatients receiving systemic anticancer therapy, and this trial aims to address that gap. Participants will be randomly assigned to receive either apixaban 2.5 mg tablets or a matching placebo, taken twice daily by mouth for six months alongside their cancer treatments. This phase 3, multicenter, double-blind, placebo-controlled trial will compare these two groups to assess if apixaban reduces the rate of VTE. The trial includes a total of 1456 patients recruited over 36 months with a follow-up period of 6 months for primary outcome measurement. During the trial, participants will be asked to take the study medication as directed and complete diaries recording treatment adherence. They will also complete quality of life and health resource use questionnaires. Researchers will monitor for blood clots confirmed by objective testing, bleeding events, survival outcomes, and patient-reported quality of life over six months. Female participants who can become pregnant are required to use effective contraception during and shortly after treatment. The studys total duration, including setup and analysis, is planned for 60 months.

Age: 16Years +All GendersPhase 3
8 locations
S

Actively Recruiting

Researchers are conducting a combined phase 2b and phase 3 clinical trial to study CSL300 Clazakizumab in adults with end stage kidney disease ESKD who are undergoing maintenance dialysis. The study aims to find the right dose of CSL300 and then evaluate its effects on cardiovascular outcomes and safety in people with systemic inflammation and either atherosclerotic cardiovascular disease ASCVD or diabetes. This multicenter, randomized, double-blind, placebo-controlled trial is designed to provide detailed information on the drugs impact and risks. The study is divided into two parts. Part 1 phase 2b focuses on identifying the optimal dose of CSL300 compared to a placebo over 12 weeks. Part 2 phase 3 assesses the efficacy and safety of CSL300 versus placebo on cardiovascular events such as cardiovascular death or heart attack over approximately 5 years. Participants receive intravenous doses of CSL300 or placebo. The placebo matches the CSL300 product minus the active ingredient. Participants will be monitored through regular assessments including blood tests to measure markers of inflammation like high-sensitivity C-reactive protein hs-CRP, other blood components, and drug levels. The trial tracks cardiovascular events and safety outcomes over the study period. The research team will also observe changes in several blood markers related to inflammation and cardiovascular health. The total follow-up may last up to about five years to fully capture long-term effects and safety.

Age: 18Years +All GendersPhase 2Phase 3
566 locations
S

Actively Recruiting

Researchers are evaluating the safety and performance of the ConvaVAC13 Ag Negative Pressure Wound Therapy System in treating chronic wounds, specifically focusing on Venous Leg Ulcers VLUs. Chronic wounds are those that heal slowly or not at all, causing pain and affecting daily life. VLUs are the most common chronic leg wounds, affecting about 1 in 100 people, and current treatments include wound cleaning, special dressings, compression therapy, and antimicrobial creams or dressings. This study aims to see if the ConvaVAC13 Ag system can improve healing outcomes for VLUs effectively and safely. The ConvaVAC13 Ag system is a device that uses negative pressure wound therapy NPWT combined with silver ions, which have antimicrobial properties. NPWT involves applying a sealed dressing connected to a vacuum pump that removes excess fluid, promotes tissue growth, and reduces bacteria in the wound. The study involves participants receiving treatment with this device on their VLUs. The system aims to support wound healing by removing harmful biofilms and promoting tissue repair. Participants will be involved in the study for at least 14 days, during which the main measurement is the percentage reduction in wound size at day 14. Researchers will monitor wound healing progress and safety throughout the treatment period. The study helps assess how well the device performs in managing VLUs, with evaluations of wound condition and patient outcomes. The total participation time may vary depending on individual wound response and healing progress.

Age: 18Years +All GendersPhase Not Applicable
7 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of the Shockwave Reducer device for patients with refractory angina pectoris who have persistent chest pain despite maximum medical therapy and are unsuitable for revascularization. This study includes a randomized, double-blind, sham-controlled trial comparing the Shockwave Reducer implant to a placebo procedure, as well as a non-randomized registry for special patient groups such as those with right coronary artery ischemia, abnormal coronary flow reserve, or mobility impairments preventing exercise testing. Participants in the randomized trial are assigned to receive either the Shockwave Reducer implant or a sham procedure with no device implanted. The registry group includes patients treated with the Shockwave Reducer who do not meet randomization criteria. The study involves implantation procedures, with evaluations of heart function and ischemia before enrollment. The trial spans multiple centers and uses a parallel study design. During the study, participants will undergo assessments including exercise tolerance tests, coronary angiography, and imaging to measure ischemia and heart function. Researchers will monitor angina symptoms using the Canadian Cardiovascular Society Angina Score and evaluate safety and effectiveness at six months. Participants are followed up for adherence to therapy and clinical status. The total study duration extends up to the primary completion date in July 2027, with ongoing long-term monitoring until 2032.

Age: 18Years +All GendersPhase Not Applicable
97 locations
G

Actively Recruiting

Researchers are conducting a global, multicenter, randomized, double-blind, placebo-controlled pivotal phase III study to evaluate overall survival in patients with newly diagnosed higher-risk myelodysplastic syndrome HR-MDS. The study compares the combination of lisaftoclax APG-2575 and azacitidine AZA against placebo combined with azacitidine. This trial aims to better understand treatment outcomes in this patient group. Participants receive either lisaftoclax orally once daily combined with azacitidine administered by hypodermic or intravenous injection once daily, or placebo orally once daily combined with azacitidine. The study includes two groups running in parallel. Treatment and follow-up continue for up to five years to assess long-term outcomes. During the study, participants will undergo regular evaluations including assessments of overall survival and safety, specifically monitoring adverse events over the five-year period. Participants must be able to complete study procedures and follow-up examinations. The study involves informed consent and ongoing monitoring to ensure participant safety and adherence.

Age: 18Years +All GendersPhase 3
155 locations
O

Actively Recruiting

Researchers are conducting an observational study to describe the characteristics and real-world clinical outcomes of patients with chronic lymphocytic leukemia CLL who received acalabrutinib in the United Kingdom through the Early Access Programme EAP. The study aims to estimate progression-free survival, overall survival, response rates, healthcare resource use, and treatment patterns in these patients. Participants in this study are patients who started first-line treatment with acalabrutinib between April 1, 2020, and April 1, 2021, as part of the UK EAP. The study is non-interventional, meaning no study drug is administered by researchers instead, data are collected retrospectively from patients clinical records according to local laws. During the study, researchers will review clinical data from patient records to measure outcomes such as progression-free survival at multiple time points up to 60 months, overall survival, response rates, and treatment interruptions. The study will provide real-world evidence on acalabrutinib use and outcomes in CLL patients over an average of five years, with no additional treatments or visits required from participants.

Age: 18Years - 130YearsAll Genders
29 locations
R

Actively Recruiting

Researchers are evaluating the drug ADX-038 in participants aged 60 years and older who have geographic atrophy GA secondary to age-related macular degeneration AMD. This Phase 2, randomized, masked, placebo-controlled study aims to compare the effects of ADX-038 with a placebo on preserving the ellipsoid zone EZ layer in the eye over 12 months. The trial will also assess the safety, pharmacokinetics, and pharmacodynamics of ADX-038. Participants will receive either subcutaneous injections of ADX-038, a siRNA duplex oligonucleotide, or a saline placebo. The study uses a parallel design where participants are randomly assigned to one of these two groups. The treatment is administered over a 12-month period, during which the impact on eye structure and function will be closely monitored. Throughout the study, participants will attend clinic visits for assessments, including high-quality fundus imaging and other study-related procedures. They must complete meningococcal and pneumococcal vaccinations as required by the protocol. Researchers will monitor the preservation of the EZ layer as the primary outcome to evaluate treatment effect, alongside safety and drug behavior in the body. The total study duration extends until August 2030, with primary outcome results expected by February 2030.

Age: 60Years +All GendersPhase 2
83 locations

1-10 of 17

1